Acadia chugs on with Alzheimer’s psychosis programme despite Phase II miss

Phase 2negativeNegative

AI Analysis

Summary

Acadia Pharmaceuticals' Phase II trial for Alzheimer's disease psychosis did not meet its endpoints, but the company plans to continue development of the program. Acadia aims to be among the first to secure approval for a therapy specifically indicated for this condition.

Clinical Trial Data

Phase

Primary Endpoint

Not Met

Outcome Details

Phase II trial did not meet endpoints

Importance:6/10

Sentiment:

-0.40

Alzheimer's diseasepsychosisPhase 2 failureCNSneurology

Related Companies

$ACAD

Read the original article

Published by Clinical Trials Arena on September 25, 2026 2:01 PM

Read Original